Immunotherapy for Squamous Cell Carcinoma of the Head and Neck Source: Society for Immunotherapy of Cancer February 26, 2025

https://reference.medscape.com/cc2/p10/cancer-immunotherapy-squamous-cell-carcinoma-head-and-neck-2025a10004tm?ecd=WNL_drugguide_260517_MSCPREF_onc_etid8346256&uac=148436CN&impID=8346256 In November 2024, the Society for Immunotherapy of Cancer (SITC) published an update to its 2019 consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). The recommendations address key clinical questions about emerging immunotherapies, and assist clinicians’ understanding of the role of these treatments in HNSCC. This specialist Medscape guideline summary includes recommendations on patient selection, therapy sequencing, response monitoring, adverse event (AE) management, and biomarker testing, and is intended for oncologists working in specialist care.